Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 6, 2008, Pages 715-722

  Kurosumi, Masafumi ^a   Takatsuka, Yuichi ^b   Watanabe, Toru ^c   Imoto, Shigeru ^d   Inaji, Hideo ^e   Tsuda, Hitoshi ^f   Akiyama, Futoshi ^g   Sakamoto, Goi ^h   Ikeda, Tadashi ⁱ   Noguchi, Shinzaburo ^j  

^a SAITAMA CANCER CENTER   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c Hamamatsu City Med Ctr Devmtl M   (Japan)

^d KYORIN UNIVERSITY   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^g CANCER INSTITUTE   (Japan)

^h Academy of Breast Pathology   (Japan)

ⁱ TEIKYO UNIVERSITY HOSPITAL   (Japan)

^j OSAKA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Anastrozole; Breast neoplasms; Histology; Neoadjuvant therapy; Pathology; Postmenopause; Tamoxifen

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER TISSUE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; JAPANESE; JAPANESE BREAST CANCER SOCIETY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; NEEDLE BIOPSY; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRIAZOLES;

EID: 41849151473     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0343-5     Document Type: Article

References (27)

1. Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR (2002) Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 87:334-338
2. ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
3. Beresford MJ, Stott D, Makris A (2007) Assessment of clinical response after two cycles of primary chemotherapy in breast cancer. Breast Cancer Res Treat, 11 July 2007 (E-pub ahead of print)
4. Buzdar AU, Valero V, Theriault RL, Frye D, Green M, Booser D, Guerra L, Sahin A, Ames F, Smith T, Singletary E, Hortobagyi GN (2003) Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 82 (Suppl 1):S69, abs 302
5. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685
6. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106:2095-2103
7. Dixon JM, Love CD, Renshaw L, Bellamy C, Cameron DA, Miller WR, Leonard RC (1999) Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 6:227-230
8. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR (2000) The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235
9. Dixon JM, Anderson TJ, Miller WR (2002) Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 38:2214-2221
10. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527-1532
11. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816
12. Huober J, Krainick-Strobel U, Kurek R, Wallwiener D (2004) Neoadjuvant endocrine therapy in primary breast cancer. Clin Breast Cancer 5:341-347
13. Kurosumi M (2003) Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients. Breast Cancer 10:97-104
14. Kurosumi M (2004) Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 11:139-147
15. Mansi JL, Smith IE, Walsh G, A'Hern RP, Harmer CL, Sinnett HD, Trott PA, Fisher C, McKinna JA (1989) Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol 25:1623-1627
16. Matsuo K, Fukutomi T, Watanabe T, Hasegawa T, Tsuda H, Akashi-Tanaka S (2002) Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas. Breast Cancer 9:75-81
17. Miller WR, Dixon JM, Cameron DA, Anderson TJ (2001) Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 79:103-107
18. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ (2003) Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 39:462-468
19. Preece PE, Wood RA, Mackie CR, Cuschieri A (1982) Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed) 284:869-870
20. Semiglazov VF, Semiglazov VV, Ivanov VG, Ziltzova EK, Dashyan GA, Kletzel A, Bozhok AA, Nurgaziev KS, Tzyrlina EV, Berstein LM (2003) Neoadjuvant endocrine therapy: exemestane (E) vs tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4N1-2MO). Breast Cancer Res Treat 82 (Suppl 1):S22, abs 111
21. Smith IE (2003) Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 86:289-293
22. Thomas JS, Julian HS, Green RV, Cameron DA, Dixon MJ (2007) Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology 51:219-226
23. Tsuda H, Kurosumi M, Akiyama F, Sakamoto G, Noguchi S, Takatsuka Y, Watanbe T, Imoto S, Inji H (2005) Histopathological assessment of anastrozole versus tamoxifen as preoperative treatment in postmenopausal women with T2-4b, N0-2, M0 breast cancer: Results from a randomized, double-blind study. J Clin Oncol (Meeting Abstracts) 23:21s, abs 570
24. Vyzula R, Dusek L, Zaloudik J, Demlova R, Klimes D, Selvekerova S (2004) Breast cancer and neoadjuvant therapy: any predictive marker? Neoplasma 51:471-480
25. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102
26. World Health Organization (2002) WHO Classification of tumours: pathology and genetics of tumours of soft tissue and bone
27. Kurosumi M, Akiyama F, Iwase T, Motomura K, Okazaki M, Tsuda H (2001) Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 8:1-2